title: Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer.
abstract: OBJECTIVE
  A phase II trial of high-dose cyclophosphamide, etoposide, and cisplatin was done.
  
  
  METHODS
  Forty-eight patients with progressive or persistent disease and previous cisplatin-based chemotherapy and no paclitaxel therapy were entered for treatment on the basis of two cycles of cyclophosphamide (4500 mg/m2), etoposide (750 mg/m2), and cisplatin (120 mg/m2).
  
  
  RESULTS
  Seventy-four cycles were delivered. Six patients died during treatment (12.5%). Of 28 with measurable disease, there was a 25% response rate and 32% had stable disease. Median time to recurrence and survival were significantly different for minimal versus bulky disease (p = 0.0089, p = 0.0008, log rank) and for platinum-sensitive versus platinum-resistant disease (p = 0.18, p = 0.0012, log-rank). The number of prior regimens was not correlated with time to progression or survival.
  
  
  CONCLUSIONS
  This study shows little advantage for high-dose protocols except for patients with a response to platinating agents and minimal residual disease.
authors.affiliation: Department of Obstetrics and Gynecology, University of Washington Medical Center, Seattle, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Cain
authors.forename: C
authors.initials: C
authors.lastname: Collins
authors.forename: S
authors.initials: S
authors.lastname: Petersdorf
authors.forename: D C
authors.initials: DC
authors.lastname: Figge
authors.forename: H K
authors.initials: HK
authors.lastname: Tamimi
authors.forename: B E
authors.initials: BE
authors.lastname: Greer
authors.forename: R B
authors.initials: RB
authors.lastname: Livingston
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D004351:Drug Resistance; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate
chemical_list: D005047:Etoposide; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide; D002945:Cisplatin